Stock comparison
BioCryst Pharmaceuticals
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BCRX
BioCryst Pharmaceuticals
Market cap
$1.89B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.29B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BCRX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 33F | 55C | GMAB |
| Benjamin Graham | 8F | 54C | GMAB |
| Philip Fisher | 33F | 38D | GMAB |
| Peter Lynch | 43D | 15F | BCRX |
| Joel Greenblatt | 4F | 66B | GMAB |
| Charlie Munger | 28F | 58C | GMAB |
| Terry Smith | 37D | 61C | GMAB |
Side-by-side metrics
| Metric | BCRX | GMAB |
|---|---|---|
| Market cap | $1.89B | $16.29B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | 7.6x | 12.0x |
| ROIC (TTM) | -121.96% | 43.78% |
| Gross margin | 18.89% | 93.88% |
| Net margin | -51.71% | 18.23% |
| Revenue CAGR 5y | 53.6% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | - | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BCRX leads on
- P/E (TTM)-vs 6.2x+178%
- Revenue CAGR 5y53.6%vs -18.45%+134%
- Debt / Equity-vs 0.1x+105%
- EV/EBIT7.6xvs 12.0x+37%
GMAB leads on
- ROIC (TTM)43.78%vs -121.96%+136%
- Net margin18.23%vs -51.71%+135%
- Market cap$16.29Bvs $1.89B+88%
- Gross margin93.88%vs 18.89%+80%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.